3.65
前日終値:
$3.46
開ける:
$3.62
24時間の取引高:
15,181
Relative Volume:
0.11
時価総額:
$4.62M
収益:
$204.80K
当期純損益:
$-8.27M
株価収益率:
-0.4012
EPS:
-9.097
ネットキャッシュフロー:
$-2.63M
1週間 パフォーマンス:
+7.35%
1か月 パフォーマンス:
-6.41%
6か月 パフォーマンス:
-43.89%
1年 パフォーマンス:
-59.60%
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Compare ADXN vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics Ltd Adr
|
3.65 | 4.62M | 204.80K | -8.27M | -2.63M | -9.097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Addex Therapeutics Ltd Adr Stock (ADXN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
Addex Therapeutics Ltd Adr (ADXN) 最新ニュース
Teyssedou Lenaic Nathanael Reports 502,423 Derivative Securities After Recent Disposals at Addex Therapeutics - kalkinemedia.com
Kalinichev Mikhail Receives 306,765 Shares and 200,000 Derivative Securities from Addex Therapeutics - kalkinemedia.com
Hill Raymond George Discloses Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - Kalkine Media
Hill Raymond George Announces Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - kalkinemedia.com
Manke Isaac Adjusts Holdings in Addex Therapeutics with 219,561 Shares and 50,000 Derivatives on September 2, 2026 - kalkinemedia.com
Addex Therapeutics LtdADR Peer Comparison – Compare with Others - Value Research
Timothy Mark Dyer Discloses 8.98% Stake in Addex Therapeutics (NASDAQ: ADXN) - kalkinemedia.com
Addex Therapeutics Ltd Sponsored ADR Revenue Breakdown – MUN:APE1 - TradingView
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness - Barchart.com
Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN) - TradingView
Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to sales forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low - Investing.com India
Addex Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 - Barchart.com
Addex Convenes Annual General Meeting 2026 - Barchart.com
ADXN - Finviz
Addex Therapeutics (NASDAQ: ADXN) flags tight cash runway and heavy partner reliance - Stock Titan
Addex Therapeutics H2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts By Investing.com - Investing.com India
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts - Investing.com
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update - Barchart.com
Addex Therapeutics announces GABAB PAM candidate data - TipRanks
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model - Barchart.com
Unusual VolumeStock ScreenerNews - Finviz
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2 - TipRanks
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model - Barchart.com
Addex Therapeutics Short Interest Drops in March - National Today
New HighStock ScreenerSnapshot - Finviz
Top GainersStock ScreenerSnapshot - Finviz
JX Luxventure Group Inc (NASDAQ:JXG) Short Interest Up 140.3% in February - Defense World
Addex Therapeutics (ADXN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Charcot Marie Tooth Disease Market on Track for Major Expansion by 2034, According to DelveInsight | DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharma - Barchart.com
ADXN SEC FilingsAddex Therapeutics Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
Addex Therapeutics (ADXN) Trading Halted Due to Volatility | ADX - GuruFocus
Addex Therapeutics Ltd_December 31, 2024 - SEC.gov
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Addex Therapeutics Ltd (ADR) (ADXN) Live Share Price, Invest From India - INDmoney
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Get insights into the top gainers and losers of Monday's pre-market session. - ChartMill
Which stocks are moving after the closing bell on Tuesday? - ChartMill
Addex Therapeutics (ADXN) Stock Forecast and Price Target 2026 - MarketBeat
Barinthus Biotherapeutics plc (BRNS) stock price, news, quote and history - Yahoo Finance UK
Barinthus Biotherapeutics plc (BRNS) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Psyence Biomedical (PBM) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Thursday's pre-market session: top gainers and losers - ChartMill
Addex Therapeutics Ltd Adr (ADXN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):